Cancer diagnostics company Exact Sciences Corp. has purchased OmicEra Diagnostics, a German startup specializing in proteomics, or large-scale protein analysis.

The deal closed Monday, according to a filing with the U.S. Securities and Exchange Commission.

In an earnings call with investors on April 26, Exact Sciences chairman and CEO Kevin Conroy mentioned that the company had agreed to acquire OmicEra as he discussed the company’s development pipeline, including its efforts to develop a multi-cancer early detection test based on multiple biomarkers. He said OmicEra is an emerging leader in proteomics biomarker discovery.

Click here to read the full article.